Tag Archives: amgn

Amgen Biosimilar Rival Delayed After Zarxio Launch

Biotech startup Coherus BioSciences (CHRS) was down more than 4% Friday after it said late Thursday that its biosimilar version of Amgen’s (AMGN) Neulasta will take longer to test than previously expected. Coherus said that it decided to increase the number of subjects in an immunogenicity study required for approval of CHS-1701, its biosimilar version of Amgen’s white-blood-cell boosting blockbuster. The company did this after seeing a slightly

Amgen, Novartis Alzheimer’s Deal Gets Cautious Praise

Big biotech Amgen (AMGN) was up in early trading Wednesday after it announced a neurology partnership with Novartis (NVS) as well as positive data on its osteoporosis drug candidate late Tuesday. Amgen and Novartis agreed to combine their research programs in Alzheimer’s disease, both of which involve drugs in the BACE (beta-site APP-cleaving enzyme-1) inhibitor class. BACE inhibitors, like the more advanced Alzheimer’s disease candidates from

Amgen’s Repatha OK’d With Similar Label To Praluent

The FDA approved Amgen’s (AMGN) cholesterol drug Repatha late Thursday, giving it a similar label to a recently approved rival from Regeneron (REGN) and Sanofi (SNY), but a slightly lower price. The agency said it had cleared Repatha, one of the new PCSK9 inhibitor class of drugs, for patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and patients with heart disease who need more